These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

91 related articles for article (PubMed ID: 11699689)

  • 21. Sequential comparison of seed loss and prostate dosimetry of stranded seeds with loose seeds in 125I permanent implant for low-risk prostate cancer.
    Saibishkumar EP; Borg J; Yeung I; Cummins-Holder C; Landon A; Crook J
    Int J Radiat Oncol Biol Phys; 2009 Jan; 73(1):61-8. PubMed ID: 18823713
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The correlation between D90 and outcome for I-125 seed implant monotherapy for localised prostate cancer.
    Ash D; Al-Qaisieh B; Bottomley D; Carey B; Joseph J
    Radiother Oncol; 2006 May; 79(2):185-9. PubMed ID: 16701911
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Is a loose-seed nomogram still valid for prostate brachytherapy in a stranded-seed era?
    Kudchadker RJ; Swanson DA; Kuban DA; Lee AK; Bruno TL; Frank SJ
    Int J Radiat Oncol Biol Phys; 2008 Oct; 72(2):623-7. PubMed ID: 18410998
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Urethral stone formation after permanent radioactive seed implant for prostate cancer.
    Steinmetz R; Barrett W
    Am J Clin Oncol; 2006 Aug; 29(4):424-5. PubMed ID: 16891876
    [No Abstract]   [Full Text] [Related]  

  • 25. [Brachytherapy for localised prostate cancer].
    Peiffert D
    Cancer Radiother; 2007 Nov; 11(6-7):373-8. PubMed ID: 17962060
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Permanent interstitial brachytherapy for the management of carcinoma of the prostate gland.
    Merrick GS; Wallner KE; Butler WM
    J Urol; 2003 May; 169(5):1643-52. PubMed ID: 12686802
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Factors predicting an increased dose to the penile bulb in permanent seed prostate brachytherapy.
    Taussky D; Haider M; McLean M; Yeung I; Williams T; Pearson S; Lockwood G; Crook J
    Brachytherapy; 2004; 3(3):125-9. PubMed ID: 15533803
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Androgen deprivation-mediated cytoreduction before interstitial brachytherapy for prostate cancer does not abrogate the elevated risk of urinary morbidity associated with larger initial prostate volume.
    Petit JH; Gluck C; Kiger WS; Laury Henry D; Karasiewicz C; Talcott JA; Berg S; Holupka EJ; Kaplan ID
    Brachytherapy; 2007; 6(4):267-71. PubMed ID: 17959423
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Brachytherapy for the treatment of prostate cancer.
    Cesaretti JA; Stone NN; Skouteris VM; Park JL; Stock RG
    Cancer J; 2007; 13(5):302-12. PubMed ID: 17921729
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Prostate-specific antigen 'bounce' after permanent 125I-implant brachytherapy in Japanese men: a multi-institutional pooled analysis.
    Satoh T; Ishiyama H; Matsumoto K; Tsumura H; Kitano M; Hayakawa K; Ebara S; Nasu Y; Kumon H; Kanazawa S; Miki K; Egawa S; Aoki M; Toya K; Yorozu A; Nagata H; Saito S; Baba S
    BJU Int; 2009 Apr; 103(8):1064-8. PubMed ID: 19040526
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Analysis of prostate-specific antigen bounce after I(125) permanent seed implant for localised prostate cancer.
    Mitchell DM; Swindell R; Elliott T; Wylie JP; Taylor CM; Logue JP
    Radiother Oncol; 2008 Jul; 88(1):102-7. PubMed ID: 18453022
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Prostate brachytherapy seed migration and dosimetry: analysis of stranded sources and other potential predictive factors.
    Fuller DB; Koziol JA; Feng AC
    Brachytherapy; 2004; 3(1):10-9. PubMed ID: 15110308
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Prostate implant nomograms for the North American Scientific 103Pd seed.
    Zheng JJ; Stevens RN
    Med Dosim; 2003; 28(3):185-8. PubMed ID: 14563438
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Advances in brachytherapy--focusing on the permanent implant for early prostate carcinoma].
    Hirokawa Y
    Gan To Kagaku Ryoho; 2003 Dec; 30(13):2056-61. PubMed ID: 14712765
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Variations in international prostate symptom scores, uroflowmetric parameters, and prostate volume after (125)I permanent brachytherapy for localized prostate cancer.
    Tanaka N; Fujimoto K; Hirao Y; Asakawa I; Hasegawa M; Konishi N
    Urology; 2009 Aug; 74(2):407-11. PubMed ID: 19376570
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Prostate high-dose-rate brachytherapy as salvage treatment of local failure after previous external or permanent seed irradiation for prostate cancer.
    Tharp M; Hardacre M; Bennett R; Jones WT; Stuhldreher D; Vaught J
    Brachytherapy; 2008; 7(3):231-6. PubMed ID: 18579446
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Permanent prostate brachytherapy: pathologic implications as assessed on radical prostatectomy specimens of broadening selection criteria for monotherapy.
    Sengupta S; Davis BJ; Mynderse LA; Sebo TJ; Cheville JC; Lohse CM; Hillman DW; Haddock MG; Wilson TM
    Urology; 2006 Oct; 68(4):810-4. PubMed ID: 17070358
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Cardiac and hepatic seed implant embolization after prostate brachytherapy.
    Nguyen BD
    Urology; 2006 Sep; 68(3):673.e17-9. PubMed ID: 16979711
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Brachytherapy of prostate cancers].
    de Crevoisier R
    Soins; 2007 Mar; (713):41-2. PubMed ID: 17419570
    [No Abstract]   [Full Text] [Related]  

  • 40. Clinical and physical determinants for toxicity of 125-I seed prostate brachytherapy.
    Wust P; von Borczyskowski DW; Henkel T; Rosner C; Graf R; Tilly W; Budach V; Felix R; Kahmann F
    Radiother Oncol; 2004 Oct; 73(1):39-48. PubMed ID: 15465144
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.